Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SQZ-AAC-HPV + nivolumab
- Development stage
- Unknown
- Lead developer
- SQZ Biotechnologies
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cell Therapies
- Administration
- Intravenous
01
Overview
**SQZ-AAC-HPV + nivolumab** is a combination immunotherapy under investigation for the treatment of HPV16-positive advanced or metastatic solid tumors. The regimen consists of SQZ-AAC-HPV, an engineered cell therapy product based on red blood cells (RBCs) modified using the Cell Squeeze® technology to carry HPV16-specific antigens (E6 and E7 oncoproteins). These engineered RBCs (Activating Antigen Carriers, AACs) are designed to mimic aged RBCs, which are naturally targeted for clearance by antigen-presenting cells (APCs), leading to endogenous CD8+ T cell priming for antitumor responses. Nivolumab is a monoclonal antibody that functions as an immune checkpoint inhibitor, specifically blocking programmed death-1 (PD-1) on T cells to enhance their activity against tumors. Together, these therapies aim to synergistically provoke targeted antitumor immunity by both priming new T cell responses and relieving immune inhibition.
- Other names
- SQZ-AAC-HPV + OpdivoSQZ® Activating Antigen Carriers + nivolumab
02
Targets
Human papillomavirus type 16 E6 oncoprotein-derived peptides presented on MHC class IpMHC-I (Peptide–MHC class I complex)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on SQZ-AAC-HPV + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SQZ-AAC-HPV + nivolumab.